RENO, Nev.--(BUSINESS WIRE)--Dec. 27, 2005--Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN) announced today that the company has successfully reached a number of its important goals for the year. During 2005, Lifeline Biotechnologies continued its worldwide marketing campaign of its MastaScope(TM). The MastaScope(TM) is a microendoscope which is inserted into a women’s breast, permitting the physician to visualize the interior of the milk ducts. The majority of breast cancers originate in the milk ducts. The preliminary market target is women patients who are experiencing nipple discharge. The Company introduced the product in China in 2004. Lifeline has recently received a product registration number from the Chinese SDA. The registration number permits Lifeline, through its Shanghai based distributor, to expand its sales efforts in China. In the latter part of 2005, Lifeline conducted physician training at hospitals in Beijing, Shanghai as well as other locations in China. In late 2005, Lifeline’s China based distributor attended one of that country’s major medical equipment trade shows, featuring the MastaScope(TM).
